CG Oncology (CGON): Assessing Valuation Following Analyst Coverage and Positive Phase 3 Trial Results [Yahoo! Finance]
CG Oncology, Inc. - Common stock (CGON)
Company Research
Source: Yahoo! Finance
This attention is supported by promising late-stage trial results for its lead bladder cancer therapy and anticipation of an FDA review next year. See our latest analysis for CG Oncology. Momentum has been strongly building for CG Oncology, as the stock has climbed over 66% in the past 90 days, capped by an 11.55% one-week share price return following analyst bullishness and positive clinical trial results. In summary, both short- and long-term total shareholder returns suggest investors see significant growth potential here. If biotech's recent surge has your attention, consider exploring more healthcare standouts with our full list: See the full list for free. But with shares surging and analyst targets pointing much higher, the key question now is whether CG Oncology remains undervalued or if the market has already priced in all the company's future growth potential. Price-to-Book of 5.1x: Is it justified? CG Oncology trades at a price-to-book (P/B) ratio of 5.1x compar
Show less
Read more
Impact Snapshot
Event Time:
CGON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGON alerts
High impacting CG Oncology, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
CGON
News
- New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder CancerGlobeNewswire
- CG Oncology Announces New Board Member and Board Transition [Yahoo! Finance]Yahoo! Finance
- CG Oncology Announces New Board Member and Board TransitionGlobeNewswire
- CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting [Yahoo! Finance]Yahoo! Finance
- CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual MeetingGlobeNewswire
CGON
Earnings
- 11/14/25 - In-Line
CGON
Sec Filings
- 11/26/25 - Form 4
- 11/26/25 - Form 3
- 11/26/25 - Form 8-K
- CGON's page on the SEC website